Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | ENO1 | P06733 | 1/20 | 0.44 |
| ▸ | BCL9 | O00512 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7604170 | 0.88 | HTR2A (0.51) | HTR2AENO1GAAALDH1A1KMT2A | |
| SCHEMBL29071595 | 0.85 | ENO1 (0.53) | ENO1ALDH1A1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL20362202 | 0.84 | ENO1 (0.50) | ENO1GAAALDH1A1KMT2AKDM4E | |
| SCHEMBL30740366 | 0.80 | HTR2A (0.53) | HTR2ABCL9CTNNB1GAAALDH1A1 | |
| SCHEMBL23616423 | 0.79 | HTR2A (0.42) | HTR2AENO1ALDH1A1KMT2AKDM4E | |
| SCHEMBL7556049 | 0.79 | LMNA (0.62) | HTR2ABCL9CTNNB1GAAALDH1A1 | |
| SCHEMBL29071597 | 0.79 | ENO1 (0.52) | ENO1GAAALDH1A1KMT2AKDM4E | |
| SCHEMBL13931737 | 0.79 | ENO1 (0.52) | ENO1ALDH1A1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL30530238 | 0.77 | PARP1 (0.37) | HTR2AENO1GAAALDH1A1KMT2A | |
| SCHEMBL14387499 | 0.77 | LMNA (0.59) | ENO1ALDH1A1KMT2AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025056913-A1 | COMPOUND AND METHOD | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2025-03-20 | — | — | WO | disclosed |
| US-20230365559-A1 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | AUCKLAND UNISERVICES LIMITED (NZ) | 2023-11-16 | — | — | US | disclosed |
| EP-4217357-A1 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | Auckland Uniservices Limited (NZ) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022064430-A1 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | AUCKLAND UNISERVICES LIMITED (NZ) | 2022-03-31 | — | — | WO | disclosed |
| EP-2336141-B1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | THRESHOLD PHARMACEUTICALS INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-9226932-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9226932-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140170240-A1 | Phosphoramidate Alkylator Prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140170240-A1 | Phosphoramidate Alkylator Prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8664204-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| EP-2336141-A2 | Phosphoramidate alkylator prodrugs | Threshold Pharmaceuticals, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20100137254-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | IMMUNOGENESIS, INC. | 2010-06-03 | — | — | US | disclosed |
| US-20100137254-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | IMMUNOGENESIS, INC. | 2010-06-03 | — | — | US | disclosed |
| US-20080132458-A1 | Hypoxia-Activated Anti-Cancer Agents | THRESHOLD PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20070060534-A1 | Anthracycline analogs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-20070060534-A1 | Anthracycline analogs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| WO-2007002931-A2 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-1173414-A1 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064864-A9 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RES CAMPAIGN TECH (GB) | 2001-12-27 | — | — | WO | disclosed |
| WO-2000064864-A1 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137254-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | TYMP, PAICS, PNP | HTR2A 3357/4885ENO1 1951/4885BCL9 525/4885 |
| US-20070060534-A1 | Anthracycline analogs | TOP2A, TOP2B, TOP1 | HTR2A 4344/4885ENO1 2606/4885BCL9 31/4885 |
| US-20080132458-A1 | Hypoxia-Activated Anti-Cancer Agents | HIF1AN, HIF1A, HYOU1 | HTR2A 2315/4885ENO1 171/4885BCL9 1894/4885 |
| US-20230365559-A1 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | DCK, DTYMK, TYMP | HTR2A 3353/4885ENO1 3441/4885BCL9 1488/4885 |
| US-20140170240-A1 | Phosphoramidate Alkylator Prodrugs | TYMP, PAICS, PNP | HTR2A 3408/4885ENO1 1993/4885BCL9 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.